NEW YORK, Aug. 23 – GeneProt has licensed DoubleTwist's Prophesy database of human genome sequence data for its proteomics research, the companies said on Thursday.
GeneProt has also licensed from DoubleTwist the commercial version of GeneCards, a searchable database that catalogs 20,000 human genes and their associations with diseases. DoubleTwist distributes GeneCards, which is linked to other human genome databases, through an agreement with the Weizmann Institute of Science in Israel, which developed the database.
The companies did not release financial details of the transaction.
DoubleTwist’s Prophecy product contains its annotated human genome sequence and software for visualizing and interpreting the genomic data. In a statement, DoubleTwist Chief Scientist Douglas Brutlag said the Prophecy database is especially useful for GeneProt because it holds more so-called alternatively spliced forms of mRNA and their associated proteins than do other genomic databases.
“Because these alternatively spliced mRNAs encode novel proteins that are expressed differentially in various tissues and disease states, use of the Prophecy suite should enable GeneProt to identify significantly more proteins and potential drug targets from a larger number of tissues than by any other means,” he said.
DoubleTwist announced 30 new subscribers to its databases in the first half of this year.